77,733 Shares in American Well Co. (NYSE:AMWL) Purchased by Takeda Pharmaceutical Co. Ltd.

Takeda Pharmaceutical Co. Ltd. acquired a new position in American Well Co. (NYSE:AMWL) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 77,733 shares of the company’s stock, valued at approximately $564,000. American Well accounts for about 2.1% of Takeda Pharmaceutical Co. Ltd.’s portfolio, making the stock its 6th largest position. Takeda Pharmaceutical Co. Ltd. owned 0.51% of American Well as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. BNP Paribas Financial Markets purchased a new position in shares of American Well during the 3rd quarter valued at $95,000. Walleye Capital LLC bought a new stake in American Well in the 3rd quarter valued at about $167,000. PDT Partners LLC purchased a new stake in American Well during the third quarter valued at about $107,000. HighTower Advisors LLC bought a new position in American Well during the third quarter worth about $355,000. Finally, Compagnie Lombard Odier SCmA bought a new position in American Well during the fourth quarter worth about $45,000. 56.05% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on AMWL shares. Needham & Company LLC restated a “hold” rating on shares of American Well in a research note on Thursday, February 13th. Truist Financial boosted their target price on shares of American Well from $10.00 to $12.00 and gave the company a “hold” rating in a report on Friday, February 14th. Wells Fargo & Company raised American Well from an “equal weight” rating to an “overweight” rating and set a $15.00 price target for the company in a report on Monday, January 13th. Morgan Stanley reduced their price target on American Well from $20.00 to $10.50 and set an “equal weight” rating for the company in a research report on Tuesday, December 17th. Finally, Stifel Nicolaus lifted their target price on American Well from $9.00 to $10.00 and gave the company a “hold” rating in a report on Thursday, February 13th. Five equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $11.90.

American Well Stock Performance

American Well stock opened at $7.93 on Thursday. American Well Co. has a fifty-two week low of $5.00 and a fifty-two week high of $17.54. The stock has a market cap of $123.82 million, a P/E ratio of -0.57 and a beta of 1.18. The firm’s fifty day moving average price is $9.99 and its 200-day moving average price is $9.31.

American Well (NYSE:AMWL) last announced its earnings results on Wednesday, February 12th. The company reported ($2.77) earnings per share for the quarter, topping analysts’ consensus estimates of ($3.04) by $0.27. American Well had a negative return on equity of 56.73% and a negative net margin of 81.83%. Sell-side analysts predict that American Well Co. will post -9.34 earnings per share for the current year.

Insider Transactions at American Well

In other news, insider Phyllis Gotlib sold 4,781 shares of the company’s stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $8.80, for a total value of $42,072.80. Following the completion of the transaction, the insider now directly owns 147,998 shares in the company, valued at approximately $1,302,382.40. This represents a 3.13 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold 5,219 shares of company stock valued at $46,454 in the last quarter. Insiders own 12.80% of the company’s stock.

American Well Company Profile

American Well Corporation, an enterprise platform and software company, delivers digitally enabling hybrid care in the United States and internationally. The company offers Converge, a cloud-based platform that enables health providers, payers, and innovators to provide in-person, virtual and automated care; and delivers virtual primary care, post-discharge follow-up, chronic condition management, virtual nursing, e-sitting, on-demand and scheduled virtual visits, specialty consults, automated care, and behavioral health, as well as specialty care programs, including dermatology, musculoskeletal care, second opinion, and cardiometabolic care to patients and members.